Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Alison J MoskowitzGunjan ShahHeiko SchöderNivetha GanesanEsther DrillHelen HancockTheresa DaveyLeslie PerezSunyoung RyuSamia SohailAlayna SantarosaNatasha GalassoRachel NeumanBrielle LiottaWilliam BlouinAnita KumarOscar B LahoudConnie Lee BatleviPaul HamlinDavid J StrausIldefonso Rodriguez-RiveraColette OwensPhilip CaronAndrew M IntlekoferAudrey HamiltonSteven M HorwitzLorenzo FalchiErel JoffeWilliam T JohnsonChristina LeeMaria Lia PalombaAriela NoyMatthew J MatasarGeorgios PongasGilles Andre SallesSantosha A VardhanaBeatriz Wills SaninGottfried von KeudellJoachim YahalomAhmet DoganAndrew D ZelenetzCraig H MoskowitzPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Second-line therapy with pembro-GVD is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to HDT/AHCT.